Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | MMP3 | P08254 | 1/20 | 0.48 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 2/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3165362 | 0.95 | MEN1 (0.57) | MEN1KMT2ANTSR1MAPTALDH1A1 | |
| SCHEMBL18760499 | 0.95 | MEN1 (0.57) | MEN1KMT2ANTSR1MAPTALDH1A1 | |
| SCHEMBL3307656 | 0.84 | MEN1 (0.68) | MEN1KMT2ANTSR1MAPTALDH1A1 | |
| SCHEMBL5262287 | 0.81 | ADORA2A (0.66) | MEN1KMT2ANTSR1MAPTALDH1A1 | |
| SCHEMBL2577307 | 0.81 | LMNA (0.61) | MEN1KMT2ANTSR1MAPTHPGD | |
| SCHEMBL10645121 | 0.81 | LMNA (0.61) | MEN1KMT2ANTSR1MAPTALDH1A1 | |
| SCHEMBL23608941 | 0.80 | L3MBTL1 (0.67) | MEN1KMT2ANTSR1MAPTALDH1A1 | |
| SCHEMBL19543731 | 0.80 | L3MBTL1 (0.67) | MEN1KMT2ANTSR1MAPTALDH1A1 | |
| SCHEMBL15894206 | 0.80 | L3MBTL1 (0.67) | MEN1KMT2ANTSR1MAPTALDH1A1 | |
| SCHEMBL338622 | 0.80 | L3MBTL1 (0.67) | MEN1KMT2ANTSR1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101646657-B | Process for producing trichloropyrimidine compound | SUMITOMO CHEMICAL CO JP | 2012-08-08 | — | — | CN | disclosed |
| US-8158787-B2 | Process for producing trichloropyrimidine compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-04-17 | — | — | US | disclosed |
| US-20100160630-A1 | PROCESS FOR PRODUCING TRICHLOROPYRIMIDINE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-06-24 | — | — | US | disclosed |
| EP-2128141-A1 | PROCESS FOR PRODUCING TRICHLOROPYRIMIDINE COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2009-12-02 | — | — | EP | disclosed |
| US-6372751-B1 | DRUGS WITH BENZENE AND PYRIMIDINE RINGS | BERLEX LABORATORIES, INC. | 2002-04-16 | — | — | US | disclosed |
| EP-1135131-A4 | ARYL AND HETEROCYCLYL SUBSTITUTED PYRIMIDINE DERIVATIVES AS ANTI-COAGULANTS | BERLEX LAB (US) | 2002-01-02 | — | — | EP | disclosed |
| EP-1135131-A1 | ARYL AND HETEROCYCLYL SUBSTITUTED PYRIMIDINE DERIVATIVES AS ANTI-COAGULANTS | BERLEX LABORATORIES, INC. (US) | 2001-09-26 | — | — | EP | disclosed |
| US-6127376-A | A BLOOD FACTOR XA ENZYME INHIBITOR TREATING A HUMAN HAVING A DISEASE-STATE CHARACTERIZED BY THROMBOTIC ACTIVITY | BERLEX LABORATORIES, INC. (US) | 2000-10-03 | — | — | US | disclosed |
| WO-2000033844-A1 | ARYL AND HETEROCYCLYL SUBSTITUTED PYRIMIDINE DERIVATIVES AS ANTI-COAGULANTS | BERLEX LATORATORIES, INC. (US) | 2000-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160630-A1 | PROCESS FOR PRODUCING TRICHLOROPYRIMIDINE COMPOUND | DPYD, TYMP, TST | MEN1 4481/4885KMT2A 3104/4885NTSR1 4233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.